Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (17)	9/25/2001 12:27:35 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 253

>> It is expected that these antibodies will be engineered to include changes in their Fc regions that will further enhance their ability to eliminate cancer cells. << And to enhance their immunogenicity? :-) Second tranche of Series A, $13.5M? Shows what big names and hot science can do. Hot science with less well-known names can be had at a significant discount. "One to watch!" Thanks fof finding this, Nigel. Rick